- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00857506
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
Longitudinal Study of Long-term (36 Month) Cognitive Outcomes in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Who Have Previously Had PET Imaging With 18F-AV-45 Injection.
The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease.
Hypothesis 1: The probability a subject will experience progressive cognitive impairment within 36 months of imaging will be greater in subjects whose 18F-AV-45 PET scan was rated amyloid positive compared to subjects whose PET scan was rated amyloid negative.
The secondary objective is to determine the stability, over 36 months of a clinical diagnosis, of AD in patients with an amyloid positive 18F-AV-45 PET.
Hypothesis 2: The diagnosis of AD will remain unchanged in patients whose PET scan were rated as amyloid positive.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Study AV-45-A11 is designed to determine if brain amyloid aggregation imaged on 18F-AV-45 PET scans is predictive of progression of cognitive impairment during the subsequent 36 months. Approximately 180 subjects enrolled in a prior clinical study (AV-45-A05[NCT00702143]) will be offered an opportunity to be studied under this protocol. The initial visit will occur as soon as possible following the AV-45-A05(NCT00702143) imaging day. Subjects who qualify for the study and their caregiver/partners will be contacted approximately 6,12,18,24 and 36 months after PET imaging in study AV-45-A05(NCT00702143), and will undergo a standardized functional and psychometric evaluation.
NOTE: This study is a clinical follow-up of subjects previously enrolled in trial 18F-AV-45-A05(NCT00702143). No new patients are being enrolled in this trial.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Arizona
-
Scottsdale, Arizona, Förenta staterna, 85258
- Research Site
-
Tucson, Arizona, Förenta staterna, 85741
- Research Site
-
-
California
-
Costa Mesa, California, Förenta staterna, 92626
- Research Site
-
-
Florida
-
Brooksville, Florida, Förenta staterna, 34613
- Research Site
-
Hallandale Beach, Florida, Förenta staterna, 33009
- Research Site
-
West Palm Beach, Florida, Förenta staterna, 33407
- Research Site
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Research Site
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- All subjects who enrolled in study AV-45-A05(NCT00702143), received 18F-AV-45, and completed a PET scan will be eligible to enroll in this trial.
Exclusion Criteria:
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Enda
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in ADAS-Cog for MCI Subjects
Tidsram: Baseline and 36 months
|
The primary analysis was the comparison in the magnitude of change from baseline in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog) between Aβ+ and Aβ- subjects in the Mild Cognitive Impairment (MCI) population at 36 months adjusting for baseline test score and age at informed consent.
ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance.
Change in ADAS-Cog scores were calculated by subtracting the baseline score from the 36 month score (last observation carried forward [LOCF]).
A change in ADAS-Cog greater than 0 indicates a deterioration in cognitive performance whereas a change in ADAS-Cog less than 0 indicates improved cognitive performance.
|
Baseline and 36 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cognitive Decline in MCI Subjects
Tidsram: Baseline and 36 months
|
The key secondary analyses compared the number of Aβ+ and Aβ- subjects in the MCI population with clinically significant deterioration in ADAS-Cog (≥4) and Clinical Dementia Rating (CDR) global score (≥0.5) and conversion in diagnosis from MCI at baseline to AD or Cognitively Normal (CN) at 36 months.
ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance.
CDR scores (range 0-3) quantify the severity of the symptoms of dementia where 0 indicates no cognitive impairment and 3 indicates severe dementia.
Changes in ADAS-Cog and CDR scores were calculated by subtracting the baseline score from the 36 month score (LOCF).
|
Baseline and 36 months
|
Change in ADAS-Cog in CN and AD Subjects
Tidsram: Baseline and 36 months
|
This analysis compared the magnitude of change from baseline in ADAS cognitive subscale (ADAS-Cog) scores between Aβ+ and Aβ- subjects in the CN and AD populations at 36 months adjusting for baseline test score and age at informed consent.
ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance.
Change in ADAS-Cog scores were calculated by subtracting the baseline score from the 36 month score (LOCF).
A change in ADAS-Cog greater than 0 indicates a deterioration in cognitive performance whereas a change in ADAS-Cog less than 0 indicates improved cognitive performance.
|
Baseline and 36 months
|
Cognitive Decline in CN and AD Subjects
Tidsram: Baseline and 36 months
|
The key secondary analyses compared the number of Aβ+ and Aβ- subjects in the CN and AD populations with clinically significant deterioration in ADAS-Cog (≥4) and CDR global score (≥0.5).
ADAS-Cog scores (range 0-70) indicate performance on a series of cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance.
CDR scores (range 0-3) quantify the severity of the symptoms of dementia where 0 indicates no cognitive impairment and 3 indicates severe dementia.
Changes in ADAS-Cog and CDR scores were calculated by subtracting the baseline score from the 36 month score (LOCF).
|
Baseline and 36 months
|
Covariate Adjusted Psychometric Score Change
Tidsram: Baseline and 36 months
|
Change from baseline by diagnostic group in covariate-adjusted psychometric assessment scores at month 36 (LOCF).
Assessments included Digit Symbol Substitution (DSS), Clinical Dementia Rating Sum of Boxes (CDR-SOB), Mini-Mental State Examination (MMSE), Wechsler Logical Memory Scale (WLMS) delayed and immediate recall, Category Verbal Fluency (CVF) animals and vegetables, Alzheimer's Disease Clinical Studies Consortium Activities of Daily Living (ADCS ADL) and Geriatric Depression Scale (GDS).
The ranges for these scales are as follows: DSS (0-93), CDR-SOB (0-18), MMSE (0-30), WLMS delayed and immediate recall (0-25), CVF animals and vegetables (0-total number of relevant items named in 60 seconds), ADCS ADL (0-78) and GDS (0-15).
For all scales except CDR-SOB and GDS a higher score indicates greater cognitive function.
For CDR-SOB and GDS a higher score indicates increased dementia or depression, respectively.
|
Baseline and 36 months
|
Correlation of Change in ADAS-Cog and SUVR
Tidsram: Baseline and 36 months
|
Correlation between change from baseline to 36 month ADAS-Cog score and baseline global average SUVR by diagnostic group is provided below.
ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance.
Change in ADAS-Cog scores were calculated by subtracting the baseline score from the 36 month score (LOCF).
A change in ADAS-Cog greater than 0 indicates a deterioration in cognitive performance whereas a change in ADAS-Cog less than 0 indicates improved cognitive performance.
Standard Uptake Value Ratio (SUVR) is the ratio of tracer uptake in the cortex and cerebellum.
SUVR values higher than 1 indicate greater amyloid burden in the cortex as compared to the cerebellum whereas scores less than 1 indicate the opposite.
|
Baseline and 36 months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 18F-AV-45-A11
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lätt kognitiv funktionsnedsättning
-
University of Texas Southwestern Medical CenterTEXAS ALZHEIMER'S RESEARCH & CARE CONSORTIUMRekryteringDemens | Lätt kognitiv funktionsnedsättning | Amnestic Mild Cognitive Impairment - aMCIFörenta staterna
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RekryteringSömnstörning | AMCI - Amnestic Mild Cognitive ImpairmentFörenta staterna
-
Dart NeuroScience, LLCAvslutadAge-Associated Memory Impairment (AAMI)Förenta staterna
-
Invendo Medical GmbHAvslutad
-
St. Boniface HospitalPizzey Ingredients; Canadian Agricultural PartnershipAktiv, inte rekryterandeMinne; Störning, mildKanada
-
Mayo ClinicRekryteringAutonom kortisolutsöndring | Mild autonom kortisolsekretion (MACS)Förenta staterna
-
Chonbuk National University HospitalAvslutadMild leverskadaKorea, Republiken av
-
Abramson Cancer Center of the University of PennsylvaniaIndragenAllvarlig eller mild toxicitet från strålbehandling och/eller kemoterapiFörenta staterna
-
Saglik Bilimleri UniversitesiAnkara UniversityRekryteringAmnestic Mild kognitiv funktionsnedsättning | Amnestisk mild kognitiv störningKalkon
-
Solta MedicalAvslutadMild till måttlig akneFörenta staterna
Kliniska prövningar på florbetapir F 18
-
Brigham and Women's HospitalAvslutadHjärtamyloidosFörenta staterna
-
Avid RadiopharmaceuticalsIndragenAlzheimers sjukdomJapan
-
Avid RadiopharmaceuticalsAvslutadProgressiv kognitiv försämringFörenta staterna
-
Avid RadiopharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS); National...AvslutadParkinsons sjukdomFörenta staterna
-
Avid RadiopharmaceuticalsAvslutadAlzheimers sjukdomFörenta staterna
-
Avid RadiopharmaceuticalsAvslutad
-
Avid RadiopharmaceuticalsAvslutadLätt kognitiv funktionsnedsättning | Alzheimers sjukdomFörenta staterna
-
Chang Gung Memorial HospitalOkänd
-
Avid RadiopharmaceuticalsAvslutadAlzheimers sjukdomFörenta staterna
-
Avid RadiopharmaceuticalsAvslutad